



## BETTER THERAPEUTICS AT A GLANCE:

- Pioneering a prescription digital therapeutics platform for treating cardiometabolic diseases.
- Currently enrolling pivotal trial for BT-001, a potential treatment for people with Type 2 diabetes. Primary endpoint data expected in Q4 2021.

### THE BIG PROBLEM

If medicine has advanced so much in recent decades, why are people getting sicker while healthcare costs increase? Cardiometabolic diseases such as diabetes and heart disease stem from behaviors related to diet, physical activity and lifestyle, yet current treatments are focused on reducing effects versus addressing root causes.

### WE DESERVE BETTER

Better Therapeutics has a proprietary platform for FDA-regulated, software-based, prescription digital therapeutics (PDTs) for treating diabetes, heart disease, and other cardiometabolic conditions at the source. Our PDTs deliver a new kind of cognitive behavioral therapy that enable changes in neural pathways of the brain that leads to lasting behavioral change. This approach holds potential to drastically lower the healthcare costs of treating multiple conditions.

Our initial focus is on:

Type 2 diabetes

Hypertension  
(high blood pressure)

Hyperlipidemia  
(high cholesterol)

### Pipeline:


BT-001 – Type 2 Diabetes – Pivotal

BT-001 – Type 2 Diabetes with Hypertension – Pilot

BT-002 – Hypertension – Pilot

BT-004 – Hyperlipidemia – Pilot

BT-005 – Hypertriglyceridemia – Pilot



### Executive Team:

**Kevin Appelbaum**, Co-Founder & Chief Executive Officer  
**Mark Berman, MD**, Chief Medical Officer  
**Kristin Wynholds**, Chief Product Officer  
**Justin Zamirowski**, Chief Commercial Officer  
**Andres Camacho**, Head of Engineering  
**Richard Morse**, Head of Clinical Operations  
**Lauren Burns**, Head of Operations

### Board of Directors:

**David Perry**, Co-Founder & Chairman  
**Andrew Armanino**  
**Richard Carmona, MD**, former U.S. Surgeon General  
**Geoffrey Parker**